6 unknown, 2 completed, 1 terminated. 2 Phase 2, 2 Phase 4, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Cyclophosphamide: new trials by email Literature Review of Cyclophosphamide trials Research Report on Cyclophosphamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on the Application of Hyperspectral Imaging Technique in CTX Treatment of IMN Microscopic hyperspectral imaging system - Hyperspectral Imaging, Idiopathic Membranous Nephropathy | Unknown | Qianfoshan Hospital | 40 | 2023-06-25 | 2023-05-09 | |
| MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN Cyclophosphamide, Mycophenolate Mofetil - Mycophenolate Mofetil, Cyclophosphamide | Phase 4 | Unknown | Second Xiangya Hospital of Central South University | 224 | 2022-07-25 | 2022-08-10 |
| Early Identification and Evaluation of Cyclophosphamide Cardiotoxicity Cardio-oncology, Hematopoietic Stem Cell Transplantation | Unknown | Kai Mu | 40 | 2021-07-10 | 2021-12-08 | |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM CYNK001-IV, CYNK001-IT - Astrocytoma, Grade IV, Giant Cell Glioblastoma | Phase 1 | Terminated | Celularity Incorporated | 3 | 2020-10-01 | 2022-08-10 |
| Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Upfront autologous HSCT - Systemic Sclerosis, Systemic Scleroses, Diffuse | Phase 4 | Completed | UMC Utrecht | 60 | 2020-09-17 | 2026-03-24 |
| Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Chidamide combined with R-GDP - Chidamide, Lymphoma, B-Cell | Phase 2 | Unknown | Fudan University | 63 | 2017-12-21 | 2017-12-14 |
| Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma G-CSF, Bortezomib, Cyclophosphamide - Myeloma, Bortezomib | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 60 | 2013-12-01 | 2014-01-06 |
| Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer paclitaxel - Breast Cancer, Paclitaxel | Not applicable | Unknown | Taizhou Hospital | 1000 | 2013-05-01 | 2013-05-07 |
| Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394) Doxorubicin, Cyclophosphamide, G-CSF - High Risk, Breast Cancer | Phase 3 | Completed | National Cancer Institute (NCI) | 60 | 1996-08-13 | 2017-08-25 |
Breast Neoplasms (2) · Cardiotoxicity (1) · Glioblastoma (1) · Glomerulonephritis, Membranous (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lupus Nephritis (1) · Lymphatic Diseases (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms, Plasma Cell (1) · Scleroderma, Diffuse (1)
Neoplasms (4) · Skin and Connective Tissue Diseases (4) · Neoplasms by Histologic Type (3) · Skin Diseases (3) · Autoimmune Diseases (2) · Breast Diseases (2) · Connective Tissue Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Glomerulonephritis (2) · Immune System Diseases (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Neoplasms by Site (2) · Nephritis (2)
Cyclophosphamide (3) · Granulocyte Colony-Stimulating Factor (2) · Bortezomib (1) · Ciprofloxacin (1) · Dexamethasone (1) · Doxorubicin (1) · Filgrastim (1) · Mycophenolic Acid (1) · Paclitaxel (1) · Tamoxifen (1)
Celularity Incorporated (1) · Fudan University (1) · Kai Mu (1) · National Cancer Institute (NCI) (1) · Qianfoshan Hospital (1) · Second Affiliated Hospital of Soochow University (1) · Second Xiangya Hospital of Central South University (1) · Taizhou Hospital (1) · UMC Utrecht (1)
China (4) · United States (2) · Italy (1) · Netherlands (1) · United Kingdom (1)
Clifford Hudis, MD (1) · Feilin Cao, MD (1) · Jacob M van Laar, MD PhD (1) · Jinxiang Fu, M.D., PhD (1) · Julia Spierings (1) · MU Kai (1) · Sharmila Koppisetti, MD (1) · Xiaochuan Wu (1)